3

PRIMARY DOCUMENT

Company: Apellis Pharmaceuticals, Inc.
Filed: April 9, 2021
Period of Report: March 30, 2021
Accession Number: 0001127602-21-013551

View Document ↗ View on SEC.gov ↗